Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The safety and performance of dCELL® Meniscus will be evaluated in 60 patients after partial replacement of the native medial or lateral meniscus with the investigational product.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament

NCT02540811

Knee Injuries

COMPLETED NA

Mesenchymal Stromal Cells for Degenerative Meniscus Injury

NCT02033525

Chronic Meniscal Injury

COMPLETED PHASE1/PHASE2

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

NCT00702741

Recovery Following Partial Medial Meniscectomy

COMPLETED PHASE1/PHASE2

Triphasic Osteochondral Scaffold for the Treatment of the OCD of the Knee: Observational Study

NCT05332288

Osteochondritis Dissecans Knee

RECRUITING

Initial Safety Evaluation of FibroFix™ Meniscus

NCT02205645

Other Tear of Medial Meniscus, Current Injury

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The dCELL® Meniscus is a novel decellularised porcine xenograft which is processed using a patented variation of Tissue Regenix's platform dCELL® technology to render it biocompatible and free from cellular material, leaving behind an acellular biological scaffold that is safe for human implantation whilst preserving the biomechanical properties. It is indicated as a biological implant to replace parts of the native meniscus in the knee for patients who present with chronic pain following failed previous meniscus repair or partial meniscectomy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dCELL® Meniscus

Group Type EXPERIMENTAL

dCELL® Meniscus

Intervention Type DEVICE

decellularised porcine xenograft

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dCELL® Meniscus

decellularised porcine xenograft

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with chronic pain following failed previous meniscus repair or partial meniscectomy
* Must be a stable, well aligned knee with ligament laxity of Grade II or less
* Osteoarthritis \<grade 3 on the Kellgren Lawrence scale
* Patients who have given written informed consent; and are willing and able to comply with entire study procedures including rehabilitation protocol

Exclusion Criteria

* Body Mass Index (BMI) greater than 35 kg/m2
* Treatment with any investigational drug or device within two months prior to screening
* Patients presenting with abnormal degenerative osteoarthritis of the joint
* Patients with a current ligament injury requiring immediate surgery or have had ligament surgery in the previous three months
* Patients using anticoagulants
* Patients on current immuno-suppressive or radiation therapy or having received such therapies within six months of screening
* Patients with diabetes or cardiovascular disease which precludes elective surgery
* Patients with documented renal disease or metabolic bone disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No